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Prevention of Atrial FibrillationIn their recent study, Macchia et al. (1) concluded that omega-3
polyunsaturated fatty acids did not signiﬁcantly decrease the rates
of recurrent atrial ﬁbrillation. However, there is an uncertainty in
interpreting the results of this study.
First, it is well-known that there is a different stereochemistry of
omega-3 polyunsaturated fatty acids if they were acquired from
differentmarine sources such asﬁsh oils andmammalian oils; omega-
3 polyunsaturated fatty acids in ﬁsh oils and mammalian oils occupy
the sn-2 and sn-1, 3 positions on the triacylglycerol molecule,
respectively, which could change the metabolism of omega-3 poly-
unsaturated fatty acids and lower the circulating levels of tri-
acylglycerols, probably causing results of randomized clinical trials
heterogeneous (1–3). The source of omega-3 polyunsaturated fatty
acids, therefore, could affect the results of the study byMacchia et al.
(1). However, the source of omega-3 polyunsaturated fatty acids was
not described in detail in the protocol and their study.
Second, it is postulated that omega-3 polyunsaturated fatty acids
could stabilize atherosclerotic plaque, possess the antithrombogenic
properties, and provoke nitric oxide–induced endothelial relaxation
(4), which is the so-called pleiotropic effect similar to that of statins
(5). In addition, omega-3 polyunsaturated fatty acids possessed the
potential antiarrhythmic properties similar to those of statins (6).
In the study by Macchia et al. (1), however, possible different
inﬂuences of omega-3 polyunsaturated fatty acids based on co-
interventions including statin therapy were not described and inter-
preted in detail. In fact, it could be very difﬁcult to assess an association
of omega-3 polyunsaturated fatty acids with the use of a statin.*Ze-Zhou Song, MS
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2010;381:1–13.ReplyIn his letter, Dr. Song raised concerns about source and compo-
sition of omega-3 polyunsaturated fatty acids (n-3 PUFAs) used in
our trial (1) and how this could affect the results of the
FORWARD (Randomized Trial to Assess Efﬁcacy of PUFA for
the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation)
trial. The product used in our trial was the same as that used in
several large clinical trials of n-3 PUFA supplementation (2,3) and
is the one approved by the U.S. Food and Drug Administration
and European Medicines Agency. One 1-g capsule per day of n-3
PUFA contained 850 to 882 mg of eicosapentaenoic acid and
docosahexaenoic acid as ethyl esters in the average ratio of 1:1$2.
The results are coherent and consistent with many other clinical
trials and systematic reviews showing that at these doses,
n-3 PUFA supplementation does not have an effect on atrial
ﬁbrillation (AF) relapse (4,5).
In his second point, he asked us to clarify the possible
interactions between n-3 PUFAs and statins in our trial. The
proportion of patients who were receiving statin treatment was
45% to 50% and was equally distributed among experimental
arms. There was no interaction between statins and n-3 PUFAs
for any of the pre-speciﬁed endpoints of the study, including
survival free of AF; death; and the composite of all-cause
mortality, nonfatal stroke, nonfatal acute myocardial infarction,
systemic embolism, development of heart failure, and severe
bleeding.*Alejandro Macchia, MD
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